Loading...
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Edmonds, K Hull, D Spencer-Shaw, Andrea Koldenhof, J Chrysou, M Boers-Doets, C Molassiotis, A
Edmonds, K
Hull, D
Spencer-Shaw, Andrea
Koldenhof, J
Chrysou, M
Boers-Doets, C
Molassiotis, A
Citations
Altmetric:
Abstract
As a group of European nurses familiar with treating patients with renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) using targeted/chemo- therapies, we aimed to review strategies for managing adverse events (AEs) associated with one targeted therapy, sorafenib.
Description
Date
2012-04
Publisher
Collections
Keywords
Type
Article
Citation
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. 2012, 16 (2):172-84 Eur J Oncol Nurs